摘要
目的探讨树突状细胞联合细胞因子诱导的杀伤细胞(dendritic cells/cytokine induced killer cells adoptive immunotherapy,DC-CIK)联合FOLFOX6方案(奥沙利铂+亚叶酸钙+5-氟尿嘧啶)治疗老年结直肠癌患者的疗效及对人类阳离子抗菌蛋白18(human cationic antimicrobial protein 18,hCAP18)和脱嘌呤脱嘧啶核酸内切酶1(apurinic aprimidinic endonuclease 1,APE1)自身抗体的影响。方法纳入90例老年结直肠癌患者,依据随机数字表法分为观察组和对照组,各45例。观察组采用DC-CIK联合FOLFOX6方案治疗,对照组采用FOLFOX6方案治疗,比较两组治疗效果及血清hCAP18和APE1自身抗体变化。结果观察组治疗总有效率高于对照组(88.9%vs 68.9%,P=0.020)。两组患者血清肿瘤标志物癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetoprotein,AFP)和糖类抗原199(carbohydrate antigen 199,CA199)水平以及hCAP18和APE1自身抗体水平均降低(均P<0.05);观察组治疗后各指标均低于对照组(均P<0.05)。观察组与对照组胃肠道反应、周围神经毒性和骨髓抑制发生率比较,差异均无统计学意义(均P>0.05)。结论 DC-CIK联合FOLFOX6方案化疗可改善老年结直肠癌患者免疫功能,下调血清hCAP18和APE1自身抗体水平,提高治疗效果。
Objective To explore the clinical efficacy of dendritic cells/cytokine induced killer cells adoptive immunotherapy(DC-CIK)combined with FOLFOX6 chemotherapy in the treatment of elderly patients with colorectal cancer and its effect on serum human cationic antimicrobial protein 18(hCAP18)and apurinic aprimidinic endonuclease 1(APE1)autoantibodies.Methods Ninety elderly patients with colorectal cancer were randomly assigned into observation group(n=45)and control group(n=45).The control group were treated with FOLFOX6 chemotherapy,the observation group were treated with DC-CIK and FOLFOX6 chemotherapy.The clinical efficacy and changes of serum hCAP18 and APE1 autoantibodies were compared between the two groups.Results The total effective rate in the observation group(88.9%)was significantly higher than that in the control group(88.9%vs 68.9%,P=0.020).The levels of serum tumor markers(carcinoembryonic antigen,alpha fetoprotein and carbohydrate antigen 199),and hCAP18 and APE1 autoantibodies were significantly decreased in both groups(all P<0.05),and each index in the observation group after treatment was significantly lower than that in the control group(P<0.05).There were no significant differences in the incidences of gastrointestinal reactions,peripheral neurotoxicity and bone marrow suppression between the observation group and the control group(all P>0.05).Conclusion DC-CIK combined with FOLFOX6 chemotherapy can improve immunity and down-regulate serum hCAP18 and APE1 autoantibodies in elderly patients with colorectal cancer,thereby improving clinical efficacy.
作者
臧晔
丁丽芳
姜藻
Zang Ye;Ding Lifang;Jiang Zao(Department of Oncology,Danyang People's Hospital,Zhenjiang 212300,China;Department of Oncology,Zhongda Hospital Southeast University,Nanjing 211000,China)
出处
《实用肿瘤杂志》
CAS
2019年第5期449-453,共5页
Journal of Practical Oncology
